Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention.
Aspirin
Eicosanoids
HIV
Inflammation
SPMs
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
01
09
2022
revised:
25
12
2022
accepted:
24
01
2023
pubmed:
16
2
2023
medline:
15
3
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
Persons with HIV (PWH) have an increased risk of cardiovascular disease (CVD) compared to HIV-seronegative individuals (SN). Inflammation contributes to this risk but the role of lipid mediators, with central roles in inflammation, in HIV infection remain to be established; further aspirin reduces CVD risk in the general population through production of some of these anti-inflammatory lipid mediators, but they have not been studied in PWH. We evaluated the relationship between plasma lipid mediators (i.e. 50 lipid mediators including classic eicosanoids and specialized pro-resolving mediators (SPMs)) and HIV status; and the impact of aspirin in PWH on regulating these autacoids. Plasma samples were obtained from 110 PWH receiving antiretroviral therapy (ART) from a randomized trial of aspirin (ACTG-A5331) and 107 matched SN samples (MACS-WIHS Combined Cohort). PWH had lower levels of arachidonic acid-derived pro-inflammatory prostaglandins (PGs: PGE Together these observations demonstrate that plasma lipid mediators profiles, some with links to systemic inflammation and CVD risk, become altered in PWH. Furthermore, aspirin intervention did not increase levels of aspirin-triggered pro-resolving lipid mediators, consistent with other reports of an impaired aspirin response in PWH. NIH.
Sections du résumé
BACKGROUND
BACKGROUND
Persons with HIV (PWH) have an increased risk of cardiovascular disease (CVD) compared to HIV-seronegative individuals (SN). Inflammation contributes to this risk but the role of lipid mediators, with central roles in inflammation, in HIV infection remain to be established; further aspirin reduces CVD risk in the general population through production of some of these anti-inflammatory lipid mediators, but they have not been studied in PWH.
METHODS
METHODS
We evaluated the relationship between plasma lipid mediators (i.e. 50 lipid mediators including classic eicosanoids and specialized pro-resolving mediators (SPMs)) and HIV status; and the impact of aspirin in PWH on regulating these autacoids. Plasma samples were obtained from 110 PWH receiving antiretroviral therapy (ART) from a randomized trial of aspirin (ACTG-A5331) and 107 matched SN samples (MACS-WIHS Combined Cohort).
FINDINGS
RESULTS
PWH had lower levels of arachidonic acid-derived pro-inflammatory prostaglandins (PGs: PGE
INTERPRETATION
CONCLUSIONS
Together these observations demonstrate that plasma lipid mediators profiles, some with links to systemic inflammation and CVD risk, become altered in PWH. Furthermore, aspirin intervention did not increase levels of aspirin-triggered pro-resolving lipid mediators, consistent with other reports of an impaired aspirin response in PWH.
FUNDING
BACKGROUND
NIH.
Identifiants
pubmed: 36791659
pii: S2352-3964(23)00033-6
doi: 10.1016/j.ebiom.2023.104468
pmc: PMC10025757
pii:
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Eicosanoids
0
Inflammation Mediators
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104468Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI069423
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069501
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI027665
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068636
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests PCT: Merck has provided her institution with funding for her research; Gilead and Lilly have also provided her institution with funding for her to conduct industry-sponsored clinical trials. PWH: Gilead has provided funding to his institution, and Merck has provided donation of study drug for NIH-sponsored trial. He has also received consulting fees and other support from Viiv Healthcare, Biotron, Gilead and Longeveron. JD is an inventor on patents related to the composition of matter and/or use of pro-resolving mediators some of which are licensed by Brigham and Women's Hospital or Queen Mary University of London for clinical development. AG: NIH, UNITAID and CDC have provided funding to her institution. TTB has received consulting fees from ViiV Healthcare, Theratechnologies, Janssen, Merck and Gilead. JAA: Atea, Emergent Biosolutions, Frontier Technologies, Gilead Sciences, GSK, Janssen, Merck, Pfizer, Regeneron and Viiv Healthcare have provided her institution with funding. RS: funding for current work was provided to institution by NIH and the ACTG network. The remaining authors have no conflicts of interest to declare.
Références
Open Forum Infect Dis. 2017 Jan 19;4(1):ofw278
pubmed: 28480270
Front Immunol. 2019 Apr 16;10:785
pubmed: 31040846
J Infect Dis. 2016 Apr 1;213(7):1074-8
pubmed: 26621909
Sci Rep. 2013;3:1940
pubmed: 23736886
Sci Rep. 2018 Nov 16;8(1):16947
pubmed: 30446683
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83
pubmed: 15471991
Circ Res. 2021 Aug 6;129(4):e54-e71
pubmed: 34238021
Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):e14-7
pubmed: 16293793
J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):280-8
pubmed: 23406976
Immunity. 2013 Oct 17;39(4):633-45
pubmed: 24138880
Elife. 2018 Feb 27;7:
pubmed: 29482717
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Semin Immunol. 2015 May;27(3):200-15
pubmed: 25857211
J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):268-73
pubmed: 19387353
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
Pathog Immun. 2017;2(3):376-403
pubmed: 29098203
JAMA Intern Med. 2013 Apr 22;173(8):614-22
pubmed: 23459863
Am J Epidemiol. 2021 Aug 1;190(8):1457-1475
pubmed: 33675224
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3963-3968
pubmed: 28356517
Sci Adv. 2019 Jun 12;5(6):eaav5463
pubmed: 31206016
BMC Infect Dis. 2013 May 04;13:203
pubmed: 23641933
J Immunol. 2014 Dec 15;193(12):6031-40
pubmed: 25392529
Immun Inflamm Dis. 2022 Jun;10(6):e629
pubmed: 35634953
Sci Adv. 2022 Feb 4;8(5):eabl5420
pubmed: 35108049
Retrovirology. 2012 Jan 11;9:4
pubmed: 22236409
Viruses. 2021 Sep 22;13(10):
pubmed: 34696320
Front Cardiovasc Med. 2022 Aug 26;9:964650
pubmed: 36093162
Front Immunol. 2021 Nov 18;12:778455
pubmed: 34868050
Blood. 2019 Jan 17;133(3):252-265
pubmed: 30404812
Clin Infect Dis. 2020 Apr 10;70(8):1764-1767
pubmed: 31414117
PLoS One. 2017 Mar 31;12(3):e0174936
pubmed: 28362840
Epidemiology. 1998 Mar;9(2):117-25
pubmed: 9504278
J Immunol. 2011 Feb 1;186(3):1735-46
pubmed: 21187448
JAMA. 2012 Jul 25;308(4):405-6
pubmed: 22820794
Open Forum Infect Dis. 2021 Mar 07;8(6):ofab109
pubmed: 34189152
Cold Spring Harb Perspect Biol. 2014 Oct 30;7(2):a016311
pubmed: 25359497
Cell. 2013 Mar 28;153(1):112-25
pubmed: 23477864
Am J Epidemiol. 1987 Aug;126(2):310-8
pubmed: 3300281
J Exp Med. 2002 Oct 21;196(8):1025-37
pubmed: 12391014
JCI Insight. 2019 Jul 11;4(13):
pubmed: 31292292
J Immunol. 2009 Aug 1;183(3):2089-96
pubmed: 19597002
Br J Pharmacol. 2017 Nov;174(22):4043-4054
pubmed: 28071789
HIV Med. 2021 Jul;22(6):434-444
pubmed: 33426758
BMC Med. 2018 Sep 24;16(1):161
pubmed: 30244671